Anastasiya Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasiya Johnson has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Allan Kachelmeier
Oregon Hearing Research Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
1 shared publication- Farshid Taghizadeh
Oregon Health and Science University Portland Oregon U.S.A.
1 shared publication - Hongzhe Li
Research Service, VA Loma Linda Healthcare System, Loma Linda, CA 92357, USA
1 shared publication - Meiyan Jiang
Department of Physiology and Pathophysiology, Shanghai Medical College of Fudan University, China
1 shared publication - Peter S. Steyger
Bellucci Translational Hearing Center, Department of Biomedical Sciences, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
1 shared publication Takatoshi Karasawa
Oregon Hearing Research Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
1 shared publication
Latest Publications
- Open Access
- 5 July 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (7) , eaaw1836
Inflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss
Aminoglycoside antibiotics are essential for treating life-threatening bacterial infections, despite the risk of lifelong hearing loss. Infections induce inflammation and up-regulate expression of candidate aminoglycoside-permeant cation channels, including transient receptor potential vanilloid-1 (TRPV1). Heterologous expression of TRPV1 facilitated cellular uptake of (fluorescently tagged) gentamicin that was enhanced by agonists, and diminished by antagonists, of TRPV1. Cochlear TRPV1 was immunolocalized near the apical membranes of sensory hair cells, adjacent supporting cells, and marginal cells in the stria vascularis. Exposure to immunostimulatory lipopolysaccharides, to simulate of bacterial infections, increased cochlear expression of TRPV1 and hair cell uptake of gentamicin. Lipopolysaccharide exposure exacerbated aminoglycoside-induced auditory threshold shifts and loss of cochlear hair cells in wild-type, but not in heterozygous Trpv1+/− or Trpv1 knockout, mice. Thus, TRPV1 facilitates cochlear uptake of aminoglycosides, and bacteriogenic stimulation upregulates TRPV1 expression to exacerbate cochleotoxicity. Furthermore, loss-of-function polymorphisms in Trpv1 can protect against immunogenic exacerbation of aminoglycoside-induced cochleotoxicity.
- 5 July 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 5 (7) , eaaw1836
Open AccessInflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss
Aminoglycoside antibiotics are essential for treating life-threatening bacterial infections, despite the risk of lifelong hearing loss. Infections induce inflammation and up-regulate expression of candidate aminoglycoside-permeant cation channels, including transient receptor potential vanilloid-1 (TRPV1). Heterologous expression of TRPV1 facilitated cellular uptake of (fluorescently tagged) gentamicin that was enhanced by agonists, and diminished by antagonists, of TRPV1. Cochlear TRPV1 was immunolocalized near the apical membranes of sensory hair cells, adjacent supporting cells, and marginal cells in the stria vascularis. Exposure to immunostimulatory lipopolysaccharides, to simulate of bacterial infections, increased cochlear expression of TRPV1 and hair cell uptake of gentamicin. Lipopolysaccharide exposure exacerbated aminoglycoside-induced auditory threshold shifts and loss of cochlear hair cells in wild-type, but not in heterozygous Trpv1+/− or Trpv1 knockout, mice. Thus, TRPV1 facilitates cochlear uptake of aminoglycosides, and bacteriogenic stimulation upregulates TRPV1 expression to exacerbate cochleotoxicity. Furthermore, loss-of-function polymorphisms in Trpv1 can protect against immunogenic exacerbation of aminoglycoside-induced cochleotoxicity.